EUVIMEDEUVIMED entdecken
Open Access

Gonadotropin-Releasing Hormone Agonist Therapy and Longitudinal Bone Mineral Density in Congenital Adrenal Hyperplasia

Myrto Eleni Flokas iD, Paul Wakim, Sarah Kollender, Ninet Sinaii iD, Deborah P Merke iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgad514 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Myrto Eleni Flokas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Children's National Hospital, Washington, DC 20010, USA. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Puberty, Precocious. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Children with congenital adrenal hyperplasia (CAH) are at risk for early puberty. Gonadotropin-releasing hormone analog (GnRHa) is frequently used and can decrease bone mineral density (BMD).

Objective

Our aim was to investigate the effect of GnRHa therapy on BMD in a longitudinal study of patients with CAH spanning both childhood and adulthood. Design and Setting Sixty-one patients with classic CAH due to 21-hydroxylase deficiency (20 treated with GnRHa) were followed with dual-energy X-ray absorptiometry (DXA) scans at puberty onset, attainment of adult height, and during early adulthood. Main Outcome Measures Whole body, lumbar spine, femoral neck, total hip, and distal radius BMD z-score at adult height. Longitudinal BMD and adult height were also assessed.

Results

Twenty patients received GnRHa for an average of 4.5 ± 2 years. There were no differences in BMD between GnRHa-treated and -untreated groups at adult height for all sites. Overall, the follow-up DXA during early adulthood showed decreases in BMD z-scores for whole body (P = .01), lumbar spine (P < .0001), femoral neck (P = .06), total hip (P = .009), and distal radius (P = .05). GnRHa treatment correlated with improved height outcomes compared to predicted height at puberty onset after adjusting for midparental height (P = .02). Patients in both groups achieved similar adult height.

Conclusion

In children with CAH, GnRHa does not compromise BMD. However, BMD decreases with time and during the second and third decades of life is a possible effect of chronic supraphysiologic glucocorticoids. Children with CAH who experience early puberty benefit from GnRHa treatment as evidenced by the positive effect on height.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Hyperplasia, CongenitalPuberty, PrecociousChildAdultHumansBone DensityLongitudinal StudiesGonadotropinsLumbar VertebraeGonadotropin-Releasing HormoneBody Height

Stichwörter der Autor:innen

CAHGnRH agonistsbone densitycongenital adrenal hyperplasiaprecocious puberty

Substanzen

GonadotropinsGonadotropin-Releasing Hormone

Autor:innen und Institutionen

  • Children's National Hospital, Washington, DC 20010, USA.
  • The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD 20892-1932, USA.
  • The National Institutes of Health Clinical Center, Bethesda, MD 20892-1932, USA.

ORCID-Profile: Myrto Eleni Flokas, Ninet Sinaii, Deborah P Merke

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Flokas, M. E., Wakim, P., Kollender, S., Sinaii, N., & Merke, D. P. (2024). Gonadotropin-Releasing Hormone Agonist Therapy and Longitudinal Bone Mineral Density in Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad514

Vancouver

Flokas ME, Wakim P, Kollender S, Sinaii N, Merke DP. Gonadotropin-Releasing Hormone Agonist Therapy and Longitudinal Bone Mineral Density in Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad514

BibTeX
@article{Flokas2024,
  author = {Flokas, Myrto Eleni and Wakim, Paul and Kollender, Sarah and Sinaii, Ninet and Merke, Deborah P},
  title = {Gonadotropin-Releasing Hormone Agonist Therapy and Longitudinal Bone Mineral Density in Congenital Adrenal Hyperplasia},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgad514}
}
Kostenlos starten →